Ascher / Gottlieb / Kirkpatrick Transfer Factor

Basic Properties and Clinical Applications
1. Auflage 2014
ISBN: 978-1-4832-1615-7
Verlag: Elsevier Science & Techn.
Format: EPUB
Kopierschutz: 6 - ePub Watermark

E-Book, Englisch, 780 Seiten

Transfer Factor: Basic Properties and Clinical Applications covers papers about transfer factor. The book presents papers on the in vitro studies of transfer factor; the characterization of transfer factor; and the animal models of transfer factor. The text also includes articles on the use of transfer factor in infectious and neoplastic diseases and transfer factor therapy. Examples of papers on transfer factor therapy include the role of transfer factor in the treatment of lymphoma cutis in Wiskott-Aldrich syndrome, transfer factor immunotherapy of rheumatoid arthritis, and transfer factor therapy in a patient with an isolated T-cell deficiency. Immunologists, pathologists, oncologists, microbiologists and people involved in the study of infectious diseases will find the book invaluable.

Autoren/Hrsg.

Ascher, Michael S.

Gottlieb, A. Arthur

Kirkpatrick, Charles H.

Inhaltsverzeichnis

1;Front Cover;1
2;Transfer Factor: Basic Properties and Clinical Applications;4
3;Copyright Page;5
4;Table of Contents;6
5;Participants;14
6;Preface;20
7;Acknowledgments;22
8;SECTION I: IN VITRO STUDIES OF TRANSFER FACTOR – I;24
8.1;CHAPTER 1. IN VITRO PROPERTIES OF LEUKOCYTE DIALYSATES CONTAINING TRANSFER FACTOR: MICRO METHOD AND RECENT FINDINGS;26
8.1.1;SPECIFICITY;28
8.1.2;REFERENCES;31
8.1.3;DISCUSSION;33
8.2;CHAPTER 2. SPECIFICITY OF TRANSFER FACTOR ACTION ON LYMPHOCYTE TRANSFORMATION;36
8.2.1;Materials and Methods;36
8.2.2;Results;37
8.2.3;Concluding Remarks;41
8.2.4;References;42
8.2.5;DISCUSSION;43
8.3;CHAPTER 3. IN VITRO COMPARISON OF TF OBTAINED FROM SKIN TEST POSITIVE AND NEGATIVE INDIVIDUALS;46
8.3.1;INTRODUCTION;46
8.3.2;MATERIALS AND METHODS;46
8.3.3;RESULTS;48
8.3.4;DISCUSSION;52
8.3.5;REFERENCES;53
8.3.6;DISCUSSION;53
8.4;CHAPTER 4. TRANSFER FACTOR: IN VITRO EFFECTS ON LYMPHOCYTE TRANSFORMATION;58
8.4.1;RESULTS;60
8.4.2;DISCUSSION;64
8.4.3;REFERENCES;65
8.4.4;DISCUSSION;66
8.5;CHAPTER 5. AUGMENTATION OF LYMPHOCYTE TRANSFORMATION BY DIALYSABLE TRANSFER FACTOR;72
8.5.1;Summary and introduction;72
8.5.2;Methodology and design;72
8.5.3;Discussion and conclusions;78
8.5.4;Acknowledgements;79
8.5.5;References;79
8.5.6;DISCUSSION;81
8.6;CHAPTER 6. LEUCOCYTE DIALYSATES REQUIRE PRECOMMITTED, ANTIGEN-REACTIVE CELLS TO AUGMENT LYMPHOCYTE PROLIFERATION;84
8.6.1;MATERIALS AND METHODS;84
8.6.2;RESULTS;85
8.6.3;CONCLUSIONS;89
8.6.4;DISCUSSION;89
8.6.5;REFERENCES;90
8.6.6;ACKNOWLEDGEMENT;91
8.6.7;DISCUSSION;92
8.7;CHAPTER 7. EXPERIMENTAL STUDIES OF TRANSFER FACTOR;98
8.7.1;1. IN VITRO STUDIES OF TF IN MAN;98
8.7.2;2. IN VITRO STUDIES OF LEUKOCYTE EXTRACTS IN THE MOUSE;104
8.7.3;REFERENCES;107
8.7.4;DISCUSSION;108
8.8;CHAPTER 8. SPECIFIC AND NONSPECIFIC EFFECTS OF TRANSFER FACTOR - DIALYZABLE LEUKOCYTE EXTRACTS;110
8.8.1;INTRODUCTION;110
8.8.2;MATERIALS AND METHODS;110
8.8.3;RESULTS;112
8.8.4;DISCUSSION;118
8.8.5;SUMMARY;120
8.8.6;ACKNOWLEDGMENTS;120
8.9;CHAPTER 9. IN VITRO CHARACTERIZATION OF THE TARGET CELL FOR TRANSFER FACTOR - DIALYZABLE LEUKOCYTE EXTRACTS;122
8.9.1;INTRODUCTION;122
8.9.2;MATERIALS AND METHODS;122
8.9.3;RESULTS;124
8.9.4;DISCUSSION;132
8.9.5;SUMMARY;133
8.9.6;ACKNOWLEDGMENTS;134
8.9.7;REFERENCES;134
8.9.8;DISCUSSION;135
9;SECTION II: IN VITRO STUDIES OF TRANSFER FACTOR – Il;138
9.1;CHAPTER 10. ACQUISITION OF MIXED CELL MIGRATION REACTIVITY BY ACTIVELY SENSITISED AND TRANSFER-FACTOR TREATED RHESUS MONKEYS;140
9.1.1;Summary and introduction;140
9.1.2;Methodology and design;141
9.1.3;Discussion and conclusions;146
9.1.4;Acknowledgements;147
9.1.5;References;147
9.1.6;DISCUSSION;148
9.2;CHAPTER 11. IN VITRO ASSAY FOR TRANSFER FACTOR USING DIRECT MIGRATION INHIBITION;152
9.2.1;References;156
9.2.2;DISCUSSION;158
9.3;CHAPTER 12. IN VITRO ASSAY FOR TRANSFER FACTOR BY MEANS OF LEUKOCYTE MIGRATION TEST (LMT);160
9.3.1;INTRODUCTION;160
9.3.2;MATERIALS AND METHODS;160
9.3.3;RESULTS;162
9.3.4;DISCUSSION;163
9.3.5;ACKNOWLEDGMENTS;166
9.3.6;REFERENCES;166
9.3.7;DISCUSSION;167
9.4;CHAPTER 13. POTENTIATING EFFECT OF TRANSFER FACTOR UPON MACROPHAGE MIGRATION INHIBITION IN VITRO;170
9.4.1;Summary and introduction;170
9.4.2;Methodology and design;170
9.4.3;Discussion and conclusions;177
9.4.4;Acknowledgements;178
9.4.5;References;178
9.4.6;DISCUSSION;179
9.5;CHAPTER 14. EFFECTS OF DIALYZABLE TRANSFER FRACTOR ON ACCUMULATION OF CYCLIC NUCLEOTIDES BY LEUKOCYTES;184
9.5.1;INTRODUCTION;184
9.5.2;METHODS;184
9.5.3;RESULTS;187
9.5.4;DISCUSSION;191
9.5.5;ACKNOWLEDGEMENT;192
9.5.6;REFERENCES;192
9.5.7;DISCUSSION;193
9.6;CHAPTER 15. STUDIES WITH IN VITRO PRODUCED TRANSFER FACTOR;196
9.6.1;MATERIALS AND METHODS;196
9.6.2;RESULTS;197
9.6.3;DISCUSSION;198
9.6.4;REFERENCES;200
9.6.5;DISCUSSION;204
9.7;CHAPTER 16. Guinea Pig "Transfer Factor" In Vitro: Physico-chemical Properties and Partial Purification;208
9.7.1;MATERIALS AND METHODS;208
9.7.2;RESULTS AND DISCUSSION;209
9.7.3;REFERENCES;215
9.7.4;DISCUSSION;216
9.8;CHAPTER 17. In Vitro Transfer of Coccidioidin and Histoplasmin Sensitivity to "Nonsensitive" Leucocytes Utilizing Whole Cell Lysates from Skin Test Positive Coccidioidin Sensitive Humans: Evidence of Cross Reactivity in a Transfer System;220
9.8.1;Introduction;220
9.8.2;Materials and Methods-Skin Testing of Human Donors;220
9.8.3;Results;221
9.8.4;DISCUSSION;223
9.8.5;DISCUSSION;225
9.9;CHAPTER 18. PRODUCTION OF SHEEP ERYTHROCYTE ROSETTE FORMING CELLS BY LYMPHOCYTES CULTURED WITH LEUCOCYTE DIALYSATES;228
9.9.1;INTRODUCTION;228
9.9.2;METHODS;228
9.9.3;RESULTS;229
9.9.4;DISCUSSION;232
9.9.5;ACKNOWLEDGEMENT;232
9.9.6;REFERENCES;233
9.9.7;DISCUSSION;234
10;SECTION III:
CHARACTERIZATION OF TRANSFER FACTOR;236
10.1;CHAPTER 19. IDENTIFICATION OF HYPOXANTHINE AS THE MAJOR COMPONENT OF CHROMATOGRAPHICALLY PREPARED TRANSFER FACTOR;238
10.1.1;MATERIALS AND METHODS;238
10.1.2;RESULTS;240
10.1.3;DISCUSSION;245
10.1.4;ACKNOWLEDGEMENTS;247
10.1.5;REFERENCES;247
10.1.6;DISCUSSION;248
10.2;CHAPTER 20. TRANSFER FACTOR - SOME BIOCHEMICAL OBSERVATIONS;252
10.3;CHAPTER 21. LOCAL TRANSFER OF DELAYED HYPERSENSITIVITY TO DOGS BY HUMAN TRANSFER FACTOR;257
10.3.1;DISCUSSION;258
10.4;CHAPTER 22. QUANTITATION OF TRANSFER FACTOR;260
10.4.1;INTRODUCTION;260
10.4.2;MATERIALS AND METHODS;260
10.4.3;RESULTS;261
10.4.4;DISCUSSION;264
10.4.5;ACKNOWLEDGMENTS;268
10.4.6;REFERENCES;268
10.4.7;DISCUSSION;269
10.5;CHAPTER 23. SOME PHYSICO-CHEMICAL AND BIOLOGICAL PROPERTIES OF A TRANSFER FACTOR PREPARATION AND ITS CLINICAL APPLICATION;270
10.5.1;Preparation of TFZ;270
10.5.2;Characteristics of TFz donors;271
10.5.3;Physico-chemical properties;271
10.5.4;Pyroqenicity;272
10.5.5;Cytotoxicity;272
10.5.6;Other characteristics;273
10.5.7;Therapeutical trials;276
10.5.8;Side effects;279
10.5.9;Concluding remarks;280
10.5.10;DISCUSSION;281
10.5.11;REFERENCES;290
10.5.12;DISCUSSION;300
10.6;CHAPTER 24. ARJA UOTILA, KAI KROHN AND JUHANI VÄISÄNEN;308
10.6.1;DISCUSSION;309
10.7;CHAPTER 25. CHROMATOGRAPHY OF TRANSFER FACTOR AND ASSAY OF FRACTIONS IN VITRO;314
10.7.1;Introduction;314
10.7.2;Methods;315
10.7.3;Results;315
10.7.4;Discussion;319
10.7.5;REFERENCES;319
10.7.6;DISCUSSION;321
10.8;CHAPTER 26. Fractionation of Rhesus Monkey Dialyzable KLH- Transfer Factor and the in vitro Assay of Specific Biologic Activity Using the Indirect MIF Assay;324
10.8.1;Sephadex Chromatography;324
10.8.2;Preparation of Supernatant Fluids from Lymphocytesb Incubated with TFd and KLH;325
10.8.3;G-25 Sephadex Chromatography and Characterization of TFd;326
10.8.4;The Effect on PEC Migration of Supernatant Fluids Derived From KLH Negative Leucocytes Incubated With TFd and KLH;329
10.8.5;Discussion;330
10.8.6;DISCUSSION;332
10.9;CHAPTER 27. BOVINE TRANSFER FACTOR: ISOLATION AND CHARACTERISTICS;334
10.9.1;DISCLAIMER STATEMENT;341
10.9.2;REFERENCES;341
10.9.3;DISCUSSION;343
10.10;CHAPTER 28. BIOLOGICAL ACTIVITY OF SUBFRACTION OF HUMAN TRANSFER FACTOR;346
10.10.1;RESULTS;347
10.10.2;DISCUSSION;354
10.10.3;REFERENCES;355
10.10.4;DISCUSSION;356
10.11;CHAPTER 29. FRACTIONATION OF TRANSFER FACTOR WITH HIGH PRESSURE LIQUID CHROMATOGRAPHY AND E-ROSETTE ENHANCING ACTIVITY OF VARIOUS FRACTIONS;358
10.11.1;High Pressure Liquid Chromatography;358
10.11.2;E-rosettes;358
10.11.3;Thin Layer Chromatography;359
10.11.4;Amino Acid Analysis;359
10.11.5;DISCUSSION;359
10.11.6;ACKNOWLEDGEMENT;360
10.11.7;REFERENCES;361
10.11.8;DISCUSSION;361
10.12;SUPPLEMENTAL GENERAL DISCUSSION;364
10.12.1;SUPPLEMENTAL GENERAL DISCUSSION;366
11;SECTION IV:
ANIMAL MODELS OF TRANSFER FACTOR;370
11.1;CHAPTER 30. CANINE TRANSFER FACTOR;372
11.1.1;MATERIALS AND METHODS;372
11.1.2;RESULTS;373
11.1.3;DISCUSSION;376
11.1.4;ACKNOWLEDGMENTS;377
11.1.5;REFERENCES;378
11.1.6;DISCUSSION;380
11.2;CHAPTER 31. "NON-SPECIFIC" EFFECTS OF HUMAN DIALYZABLE TRANSFER FACTOR;382
11.2.1;DISCUSSION;391
11.3;CHAPTER 32. TRANSFER OF CELLULAR REACTIVITY TO 3 NONHUMAN PRIMATE SPECIES WITH HUMAN AND BABOON TRANSFER FACTOR;394
11.3.1;Materials and Methods;394
11.3.2;Discussion;400
11.3.3;Acknowledgements;401
11.3.4;References;401
11.3.5;DISCUSSION;402
11.4;CHAPTER 33. PREVENTION OF HERPES SIMPLEX VIRUS TYPE 1 FATAL DISSEMINATION IN PRIMATES WITH HUMAN TRANSFER FACTOR;404
11.4.1;Materials and Methods;404
11.4.2;Results;406
11.4.3;Discussion;407
11.4.4;Acknowledgements;409
11.4.5;References;409
11.5;CHAPTER 34. TRANSFER OF DELAYED HYPERSENSITIVITY TO MICE WITH HUMAN IMMUNE CELL EXTRACTS;410
11.5.1;Hypothesis;417
11.5.2;Summary;417
11.5.3;Acknowledgements;418
11.5.4;References;418
11.5.5;DISCUSSION;419
11.6;CHAPTER 35. Human Transfer Factor in Guinea Pigs: Further Studies;422
11.6.1;ACKNOWLEDGMENTS;427
11.6.2;REFERENCES;427
11.6.3;DISCUSSION;429
11.7;CHAPTER 36. HUMAN TRANSFER FACTOR IN GUINEA PIGS: PARTIAL PURIFICATION OF THE ACTIVE COMPONENT;432
11.7.1;INTRODUCTION;432
11.7.2;MATERIALS AND METHODS;432
11.7.3;RESULTS;436
11.7.4;DISCUSSION;444
11.7.5;ACKNOWLEDGEMENTS;445
11.7.6;REFERENCES;445
11.7.7;DISCUSSION;447
11.8;CHAPTER 37. HUMAN TRANSFER FACTOR: TRIALS WITH AN ASSAY IN GUINEA PIGS;448
11.8.1;DISCUSSION;452
11.8.2;REFERENCES;453
11.8.3;DISCUSSION;453
11.9;Correlation of in vivo and in vitro activity of guinea pig transfer factor;454
12;SECTION V:
TRANSFER FACTOR IN INFECTIOUS DISEASES;460
12.1;CHAPTER 38. Transfer Factor Therapy of Chronic Aggressive Hepatitis;462
12.1.1;DISCUSSION;470
12.2;CHAPTER 39. Attempted Immunotherapy with Dialyzable Transfer Factor in Hepatitis B Carrier Chimpanzees: Induction of Delayed Hypersensitivity to Hepatitis B Surface Antigen (HBsAg);472
12.2.1;MATERIALS AND METHODS;472
12.2.2;RESULTS;474
12.2.3;DISCUSSION;477
12.2.4;SUMMARY;478
12.2.5;ACKNOWLEDGMENTS;479
12.2.6;REFERENCES;479
12.3;CHAPTER 40. TRANSFER FACTOR TREATMENT OF VIRAL DISEASES IN MILWAUKEE;480
12.3.1;DISCUSSION;486
12.4;CHAPTER 41. PRELIMINARY RESULTS ON THE SAFETY AND EFFICACY OF TRANSFER FACTOR IN LEPROSY;488
12.4.1;REFERENCES;497
12.4.2;DISCUSSION;498
12.5;CHAPTER 42. CLINICAL AND IMMUNOLOGIC RESULTS OF TRANSFER FACTOR THERAPY IN COCCIDIOIDOMYCOSIS;500
12.5.1;INTRODUCTION;501
12.5.2;MATERIALS AND METHODS;502
12.5.3;RESULTS;503
12.5.4;References and Notes;514
12.5.5;DISCUSSION;514
12.6;CHAPTER 43. COMBINATION TRANSFER FACTOR-AMPHOTERICIN B THERAPY IN A CASE OF CHRONIC MUCOCUTANEOUS CANDIDIASIS: A CONTROLLED STUDY;518
12.6.1;CASE REPORT;518
12.6.2;MATERIALS AND METHODS;518
12.6.3;RESULTS;519
12.6.4;DISCUSSION;520
12.6.5;REFERENCES;522
12.6.6;DISCUSSION;523
12.7;CHAPTER 44. Immunological Reconstitution of Chronic Mucocutaneous Candidiasis with Transfer Factor and Fetal Thymic Tissue;526
12.7.1;Discussion;529
12.7.2;References;531
12.7.3;DISCUSSION;531
12.8;CHAPTER 45. TRANSFER FACTOR THERAPY OF DISSEMINATED HISTOPLASMOSIS;532
12.8.1;INTRODUCTION;532
12.8.2;METHODS AND MATERIALS;532
12.8.3;CASE REPORT;534
12.8.4;COMMENT;536
12.8.5;REFERENCES;537
12.8.6;DISCUSSION;537
12.9;CHAPTER 46. SUPPLEMENTAL GENERAL DISCUSSION;538
12.9.1;SUPPLEMENTAL GENERAL DISCUSSION;539
13;SECTION VI:
TRANSFER FACTOR IN NEOPLASTIC DISEASES;544
13.1;CHAPTER 47. TRANSFER FACTOR IMMUNOTHERAPY IN CANCER;546
13.1.1;MATERIALS AND METHODS;546
13.1.2;RESULTS;547
13.1.3;DISCUSSION;552
13.1.4;REFERENCES;552
13.1.5;DISCUSSION;553
13.2;CHAPTER 48. An Unusual Metastatic Lesion in a Patient with Osteosarcoma Receving Tumor Specific Transfer Factor;560
13.2.1;DISCUSSION;562
13.3;CHAPTER 49. IMMUNOTHERAPY OF HUMAN NEOPLASMS WITH TRANSFER FACTOR;566
13.3.1;REFERENCES;571
13.3.2;DISCUSSION;572
13.4;CHAPTER 50. ADJUNCTIVE TRANSFER FACTOR IN OSTEOGENIC SARCOMA: I. CLINICAL IMPLICATIONS OF CHEMOTHERAPY AND IMMUNOTHERAPY;576
13.4.1;MATERIALS, METHODS AND RESULTS;578
13.4.2;REFERENCES;583
13.4.3;DISCUSSION;584
13.5;CHAPTER 51. Case Discussion: Undifferentiated Sarcoma;585
13.6;CHAPTER 52. ADJUNCTIVE TRANSFER FACTOR IN OSTEOGENIC SARCOMA: II. METHODOLOGY AND RESULTS OF THE IMMUNOLOGICAL STUDIES;586
13.6.1;DISCUSSION;589
13.6.2;REFERENCES;591
13.6.3;DISCUSSION;593
13.7;CHAPTER 53. TRANSFER FACTOR THERAPY IN DISSEMINATED NEOPLASMS;596
13.7.1;INTRODUCTION;596
13.7.2;METHODS;596
13.7.3;RESULTS;597
13.7.4;DISCUSSION;600
13.7.5;CONCLUSIONS;601
13.7.6;BIBLIOGRAPHY;601
13.7.7;DISCUSSION;602
13.8;CHAPTER 54. CLINICAL TRIALS WITH TRANSFER FACTOR;606
13.8.1;MATERIALS AND METHODS;606
13.8.2;CONCLUSION;612
13.8.3;ACKNOWLEDGEMENT;613
13.8.4;REFERENCES;613
13.8.5;DISCUSSION;613
14;SECTION VII: TRANSFER FACTOR THERAPY;616
14.1;CHAPTER 55. THE ROLE OF TRANSFER FACTOR IN THE TREATMENT OF LYMPHOMA CUTIS IN WISKOTT-ALDRICH SYNDROME;618
14.1.1;CASE REPORT;618
14.1.2;DISCUSSION;620
14.1.3;ACKNOWLEDGEMENT;621
14.1.4;REFERENCES;621
14.1.5;DISCUSSION;621
14.1.6;Acknowledgements;632
14.1.7;References;632
14.1.8;DISCUSSION;633
14.2;CHAPTER 56. The Effect of a Chromatographically Purified Transfer Factor Component on Juvenile Rheumatoid Arthritis;636
14.2.1;DISCUSSION;637
14.3;CHAPTER 57. TRANSFER FACTOR IMMUNOTHERAPY OF RHEUMATOID ARTHRITIS;640
14.3.1;References;644
14.3.2;DISCUSSION;644
14.4;CHAPTER 58. Transfer Factor Therapy in a Patient with an Isolated T-cell Deficiency;646
14.4.1;Case History;646
14.4.2;Immunological Studies: B-cell System;646
14.4.3;Discussion;649
14.4.4;References;650
14.4.5;DISCUSSION;651
14.5;CHAPTER 59. EFFECTS OF TRANSFER FACTOR IN WALDENSTROM'S MACROGLOBULINEMIA AND MULTIPLE MYELOMA;656
14.5.1;REFERENCES;660
14.5.2;DISCUSSION;661
14.5.3;DISCUSSION;670
14.6;CHAPTER 60. TRANSFER FACTOR TREATMENT OF PATIENTS WITH MULTIPLE SCLEROSIS;672
14.6.1;INTRODUCTION;672
14.6.2;RESULTS;675
14.6.3;DISCUSSION;679
14.6.4;Acknowledgement;681
14.6.5;REFERENCES;681
14.6.6;DISCUSSION;683
14.7;CHAPTER 61. TRANSFER OF PROTECTIVE IMMUNITY TO FRIEND LEUKEMIA VIRUS BY CELL FREE EXTRACTS OF IMMUNE LYMPHOID CELLS;686
14.7.1;General Experimental Procedures;686
14.7.2;Experimental Results;687
14.7.3;Discussion and Conclusions;691
14.7.4;Summary;693
14.7.5;Acknowledgements;694
14.7.6;References;694
14.7.7;DISCUSSION;695
14.8;CHAPTER 62. LEUKAPHERESIS OF CANCER PATIENTS FOR ADOPTIVE IMMUNOTHERAPY;698
14.8.1;A. IN VIVO PARAMETERS;699
14.8.2;B. IN VITRO PARAMETERS;700
14.8.3;DISCUSSION;702
14.8.4;REFERENCES;703
14.8.5;DISCUSSION;704
14.9;CHAPTER 63. TRANSFER FACTOR AND SKIN GRAFTS;706
14.9.1;DISCUSSION;707
14.10;CHAPTER 64. ON THE NATURE OF TRANSFER FACTOR;710
14.10.1;REFERENCES;713
14.11;CHAPTER 65. INVESTIGATIONS ON THE TRANSFER OF CELLULAR IMMUNITY IN ANIMAL MODEL SYSTEM BY THE TRANSFER FACTOR;714
14.12;CHAPTER 66. HUMAN "TRANSFER FACTOR" ACTIVITY IN GUINEA PIGS;718
14.12.1;SUMMARY;718
14.12.2;INTRODUCTION;718
14.12.3;MATERIALS AND METHODS;719
14.12.4;RESULTS;721
14.12.5;DISCUSSION;724
14.12.6;REFERENCES;725
14.12.7;DISCUSSION;726
14.13;CHAPTER 67. Lymphocyte Antigen Sensitivity As A Requirement for a Blastogenic Response to Transfer Factor;728
14.14;CHAPTER 68. Leishmania enriettii Infections in Guinea Pigs and Transfer Factor Obtained from Convalescent yet Immune Animals;732
14.14.1;Methods and Materials;732
14.14.2;Results and Discussion;733
14.14.3;References;735
14.14.4;DISCUSSION;736
14.15;CHAPTER 69. CLINICAL EVALUATION OF THE EFFECTS OF TRANSFER FACTOR ON MULTIPLE SCLEROSIS;738
14.15.1;Introduction;738
14.15.2;Patient Selection and Procedure;738
14.15.3;Preparation of Transfer Factor;738
14.15.4;Case Descriptions Are Given in Table I;739
14.15.5;REFERENCES;743
14.15.6;DISCUSSION;743
15;SECTION VIII: KEYNOTE ADDRESS;744
15.1;CHAPTER 70. A BIOCHEMIST'S VIEW OF THE MEDIATORS OF CELLULAR IMMUNITY, WITH SPECIAL REFERENCE TO TRANSFER FACTOR;746
15.1.1;SUMMARY;759
15.1.2;REFERENCES;760
15.2;CHAPTER 71. SUMMATION;764
15.2.1;Biochemistry;764
15.2.2;In Vitro Assay Systems;766
15.2.3;In Vitro Production of TF;768
15.2.4;In Vitro Pitfalls;768
15.2.5;Newer Animal Models for TF Activity;769
15.2.6;Clinical Applications;773
16;Subject Index;778

Leseproben

Participants

M. Al-Ibrahim,     Infectious Disease and Immunology Division, Department of Medicine, New York University Medical Center, New York, New York 10016

L.A. Andron,     Physical Sciences Division, USAMRIID, Fort Detrick, Maryland 21701

L.J. Antunes,     Department de Biochimicae Immunologia, Institute de Cinencias Biologicas, University Federal De Minas Gerais, Caixa Postal 24B6, 30000–Belo Horizonte–MG, Brasil

M.P. Arala-Chaves,     Department of Basic and Clinical Immunology and Microbiology, Medical University of South Carolina, Charleston, South Carolina 29401

W.D. Armstrong,     Department of Pathology, Provincial Laboratory, Edmonton, Alberta, Canada T6G252

M.S. Ascher,     Medical Division, USAMRIID, Fort Detrick, Frederick, Maryland 21701

R.L. Aspinall,     Searle Laboratories, Chicago, Illinois 60680

M. Ballow,     Department of Pediatrics, University of Connecticut Health Center, Farmington, Connecticut 06032

P. Baram,     Division of Immunology, The Research Institute, American Dental Association, Chicago, Illinois 60611

A. Basten,     Department of Medicine, Immunology Unit, The University of Sydney, Sydney, N.S.W. 20006, Australia

J. Bearden,     Division of Oncology, Wilford Hall, USAF Medical Center, Lackland AFB, Texas 78236

P.H. Bell,     Lederle Laboratories, Pearl River, New York 10965

C. Benz,     Immunology Lab. #1, British Columbia Cancer Institute, 2656 Heather Street, Vancouver, B.C., V 5Z–3J3, Canada

M. Blaese,     National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014

J. Booss,     Department of Microbiology, Jefferson Medical College, Philadelphia, Pennsylvania 19107

W. Borkowsky,     Infectious Disease and Immunology Division, Department of Medicine, New York University Medical Center, New York, New York 10016

R.M. Bukowski,     Cleveland Clinic Foundation, Cleveland, Ohio 44106

D.R. Burger,     Surgical Research Laboratory, Veterans Administration Hospital, Portland, Oregon 97207

V.S. Byers,     Department of Medicine, University of California Medical Center, San Francisco, California 94122

A. Catanzaro,     Department of Medicine, University of California, San Diego, La Jolla, California 92037

R.S. Chang,     Department of Medical Microbiology, University of California, Davis School of Medicine, Davis, California 95611

M. Chase,     The Rockefeller University, New York, New York 10021

B.A. Clinton,     P.O. Box 5110, Chicago, Illinois 60680

L. Cohen,     Infectious Disease and Immunology Division, Department of Medicine, New York Univeristy Medical Center, New York, New York 10016

T. Conger,     Department of Microbiology and Public Health, Michigan State University, East Lansing, Michigan 48823

W. Cozine, Jr.,     Southwestern Clinic and Research Foundation, Agriculture Science Building, University of Arizona, Tucson, Arizona 85721

T. Darrow,     Clinical Pathology, SUH, SUNY, Syracuse, New York 13210

J.R. David,     Robert B. Brigham Hospital, Boston, Massachusetts 02102

S. Deodhar,     Cleveland Clinic, Cleveland, Ohio 44106

R. Douglas,     Blood Transfusion Center, Park Avenue, Aukland 3, New Zealand

C.G. Drube,     Chemotherapy Department, Schering Corporation, Bloomfield, New Jersey 07003

D.C. Dumonde,     Division of Immunology, Kennedy Institute of Rheumatology, Bute Gardens, Hammersmith, London W6 7GW, England

W.A. Dunnick,     Immunobiology Research Center, 5104 Physics–Pharm. Building, Madison, Wisconsin 53706

S. Erhan,     University of Pennsylvania, School of Veterinary Medicine, Philadelphia, Pennsylvania 19174

A.D. Erickson,     VA Hospital, Davis Park, Providence, Rhode Island 02908

R. Ferebee,     Department of Microbiology, Pharm.-Micro. Building, University of Arizona, Tucson, Arizona 85721

M. Finklestein,     Infectious Disease and Immunology Division, Department of Medicine, New York University Medical Center, New York, New York 10016

M.J. Florey,     Research Fellow, N. W. Reg. American Red Cross Blood Bank, Portland, Oregon 97213

L. Foster,     Institute of Microbiology, Rutgers University, New Brunswick, New Jersey 08903

L. Frenkel,     Georgetown University Medical Center, Gorman Building, 3800 Reservoir Road, N.W., Washington, D.C. 20007

H. Friedman,     Department of Microbiology, Albert Einstein Medical Center, Northern Division, York and Tabor Road, Philadelphia, Pennsylvania 19141

D.A. Fuccillo,     NINCDS, Building 36, National Institutes of Health, Bethesda, Maryland 20014

H.H. Fudenberg,     Department of Basic and Clinical Immunology and Microbiology, Medical University of South Carolina, Charleston, South Carolina 29401

P.R. Glade,     Department of Pediatrics, University of Miami School of Medicine, Biscayne Annex, Miami, Florida 33152

A.A. Gottlieb,     Department of Microbiology and Immunology, Tulane Medical School, New Orleans, Louisiana 70112

J.M. Goust,     Department of Basic and Clinical Immunology and Microbiology, Medical University of South Carolina, Charleston, South Carolina 29401

J.R. Graybill,     The University of Texas, Health Science Center at San Antonio, San Antonio, Texas 78284

G. Griffin,     Biology Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830

P. Grob,     Immunologisches Labor. der Med. Universitatsklinik im Institut fur Med. Mikrobiologie, Gloriastrasse 32, 8006 Zurich, Switzerland

J. Gutterman,     Division of Experimental Therapeutics, University of Texas Cancer Center, M. D. Anderson Hospital, Houston, Texas 77025

A.S. Hamblin,     Division of Immunology, Kennedy Institute of Rheumatology, Bute Gardens, Hammersmith, London W67DW, England

R.C. Hastings,     Pharmacology Research Department, U.S. Public Health Service Hospital, Carville, Louisiana 70721

L.R. Heim,     Department of Laboratory Medicine, Columbia Hospital, Milwaukee, Wisconsin 53211

E. Hersh,     Division of Experimental Therapeutics, University of Texas Cancer Center, M. D. Anderson Hospital, Houston, Texas 77025

P. Hoffman,     NIAID, LCI, Building 10, National Institutes of Health, Bethesda, Maryland 20014

R.S. Holzman,     Infectious Disease and Immunology Division, Department of Medicine, New York University Medical Center, New York, New York 10016

M. Hornung,     Department of Surgery, Tulane Medical School, New Orleans, Louisiana 70112

T.K. Huard,     Division of Immunology, The Research Institute, American Dental Association, Chicago, Illinois 60611

G.B....